0.13%SPY 128.17 
0.54%WM 4.65 20.10%
Digg
Del.icio.us
Newsvine 
Facebook
Stumbleupon
The Food and Drug Administration warned one more time about the risks of Novartis and Roche transplant drugs for pregnant woman.
| NVS | 57.98 |  -0.49 |
On Friday, the U.S. health regulator referred to Roche's drug CellCept and Novartis AG' drug Myfortic on a warning letter. In October both were linked to reports of miscarriages and birth defects when prescribed to pregnant women.
In November the companies changed the labels adding a strong warning about the risks. The FDA said it hasn't received more reports of pregnancy related problems but said the letter was a reminder to doctors who prescribe the drugs.
The agency encourages doctors to make sure their organ transplant patients are not pregnant before prescribing the medicine and also a reminder for the prescription for the approved use of preventing rejection of transplanted organs.
The FDA said it will continue working with both companies to halt use of the products by pregnant women.
Shares of Novartis were lastly trading 0.10 percent down to $51.36 in the New York Mercantile Exchange in after hours electronic trading Friday.
Gold experienced a second day of heavy liquidations, following yesterday oil-led and hawkish Fed-induced rout. Significant losses in the euro wer...
China's largest city and the host of a dozen Olympic soccer matches started...
Swedish specialty steelmaker SSAB reported second-quarter pretax profit above market expectations on Thursday and said the global steel market sh...
|
Professional Website Design For Corporate - Get a Free Quote Today
Find the most up to date research from leading investment firms to make the most informed investing decisions
Partners  
|
© 2008 The Ibtimes Company. All Rights Reserved. Terms of service | Privacy Policy | Advertising | About Us | Contact Us | Archives
EMAIL
PRINT
RSS
SHARE
